George Ng - Jan 30, 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Executive Officer, Director
Signature
/s/ George Ng, by Neda A. Sharifi, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Jan 30, 2024
Transactions value $
$27,000
Form type
4
Date filed
1/31/2024, 04:37 PM
Previous filing
Oct 12, 2023
Next filing
Oct 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Purchase $27K +10K +100% $2.70 20K Jan 30, 2024 By Family Trust F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 Reflects that shares previously reported as directly held by the reporting person were held in a trust.